Patents Examined by Bailey Buchanan
  • Patent number: 12624398
    Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods useful for detecting long non-coding RNAs (lncRNA) in medulloblastoma. In one embodiment, the present invention provides a method comprising detecting lnc RNA HLX2-7 in a biological sample obtained from a patient having or suspected of having medulloblastoma. In certain embodiments, detecting step is performed using RNA fluorescence in situ hybridization (FISH) assay. In specific embodiments, the biological sample is a tissue sample. In particular embodiments, the tissue sample is a formalin-fixed paraffin-embedded (FFPE) sample. In a specific embodiment, the FISH assay comprises oligonucleotide probes that hybridize to lncHLX2-7 (SEQ ID NO:200) and branched DNA signal amplification.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: May 12, 2026
    Assignee: The Johns Hopkins University
    Inventors: Joseph Ranjan Perera, Keisuke Katsushima
  • Patent number: 12618111
    Abstract: The present invention describes methods of diagnosing inflammatory bowel disease, including but not limited to Crohn's Disease (CD), Ulcerative Colitis (UC), and/or Medically Refractive Ulcerative Colitis (MR-UC), using RNASET2, TL1A and/or IFN-?. The invention further provides a process for patient identification and/or stratification.
    Type: Grant
    Filed: October 28, 2021
    Date of Patent: May 5, 2026
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Rebecca Gonsky, Stephan R. Targan, Richard L. Deem, Philip Fleshner, Dermot P. Mcgovern, Janine Bilsborough
  • Patent number: 12612658
    Abstract: Compositions and methods for amplifying RNA by replication using transcription polymerases are disclosed. Such replicated RNAs can be used in various applications such as RNAi therapeutics, diagnostic probes, RNA sequencing, directed evolution of RNA aptamers without intermediate conversion to DNA, and RNA vaccines. The transcription polymerases comprise T7 bacteriophage RNA polymerase.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: April 28, 2026
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Nimit Jain, Andrew Z. Fire, Lucas R. Blauch, Sindy K. Y. Tang, Karen L Artiles, Julia T. Garcia-Daou, Y. Whitney Yin, Michal R. Szymanski
  • Patent number: 12577623
    Abstract: The present invention relates to a method for providing information for colorectal cancer diagnosis, a composition for diagnosing colorectal cancer, and a kit comprising same, and, more particularly, to: a method for providing information for colorectal cancer diagnosis by using a primer for specifically amplifying plural methylated colorectal cancer marker genes; a composition for diagnosing colorectal cancer; and a kit comprising same.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: March 17, 2026
    Assignee: GENOMICTREE, INC.
    Inventors: Sungwhan An, TaeJeong Oh
  • Patent number: 12473594
    Abstract: Provided is a chemical tagging-based method for modified nucleoside sequencing, enrichment, and measurement, comprising reacting a thiol compound with an N-hydroxymethyl chemically modified nucleoside, then using a chemical tag such as biotin to perform tagging, and then enriching and sequencing or measuring. In the method of the present invention, selective chemical tagging is used, and the selectivity of the chemical reaction ensures result specificity and reduces false positive results.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: November 18, 2025
    Assignee: PEKING UNIVERSITY
    Inventors: Guifang Jia, Ye Wang, Shunqing Dong
  • Patent number: 12371739
    Abstract: Provided are processes for the use of a single dried blood sample for the preparation of test samples including targets of differing structures. The processes allow the same dried blood sample to be used for preparation of a first test sample including a non-nucleic acid target, and the same dried blood sample to be subsequently processed for preparation of a test sample that includes a nucleic acid target whereby the processes preserve the ability of the nucleic acid to be detected in subsequent detection assays following prior isolation of non-nucleic acid targets.
    Type: Grant
    Filed: February 2, 2022
    Date of Patent: July 29, 2025
    Assignee: Revvity Health Sciences, Inc.
    Inventors: Stephanie Dallaire, Jordan Haddock, Cristina Gutierrez-Mateo, Anna M. Potier, Joseph D. Trometer